PTC Therapeutics Inc. recently delivered a presentation highlighting their achievements and progress in 2024 and outlining plans for 2025. The company successfully met all development milestones in 2024, achieved a strong cash position, and recorded outstanding revenue performance, with a total revenue of $807 million. In 2024, PTC submitted four U.S. regulatory approval applications, including the AADC Gene Therapy BLA, which was approved, and three NDAs for Sepiapterin PKU, Translarna nmDMD, and Vatiquinone Friedreich's Ataxia, all of which were accepted. The company's advancements stem from their innovative scientific platforms. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.